William H. Rastetter
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| DARE | ▲ Buy | Grant | 38,862 | $0 | 6/30/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,318 | $0 | 5/21/2026 | View on chart |
| FATE | ▲ Buy | Option Exercise | 25,000 | $42K | 5/5/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 18,000 | $862K | 11/5/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 18,000 | $2.7M | 11/5/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,869 | $0 | 5/22/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 30,000 | $1.3M | 5/5/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 30,000 | $3.3M | 5/5/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 14,250 | $2.1M | 8/15/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 20,000 | $260K | 1/2/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 11,044 | $1.5M | 1/2/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 7,625 | $97K | 5/1/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 4,300 | $436K | 5/1/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 10,765 | $137K | 4/21/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 6,034 | $634K | 4/21/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 903 | $95K | 4/19/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,610 | $20K | 4/19/2023 | View on chart |
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 20,000 | $133K | 4/1/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 10,728 | $1.0M | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
DARE Receives New Patents for HPV and Cervical Treatments
Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.
DARE Receives New Patents for HPV and Cervical Treatments. Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.